Fondazione Irccs Istituto Nazionale Dei Tumori

University of Pennsylvania

Other

Consiglio Nazionale Delle Ricerche

Fondazione Istituto Italiano Di Tecnologia

Universidade De Santiago De Compostela

UniversitÁ Degli Studi Di Genova

Istituto Nazionale Per Lo Studio E La Cura Dei Tumori

Advanced Accelerator Applications Sa

UniversitÀ Degli Studi Di Verona

Fondazione Irccs “Instituto Nazionale Dei Tumori”

Mariangela Figini

Silvana Canevari

Daniel J Powell

George Coukos

Teresa Pellegrino

Vito Di Cioccio

Franck Martin

Juan Granja

Alessandra Quarta

Alessandro Massimo Gianni

Giulio Fracasso

Massimo Di Nicola

Sara Cingarlini

Margherita Cattozzo

Marco Colombatti

Giovanni Maurizi

Alessandro Satta

Markus Barthel

Marco Cassani

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FRα binding domain is fully human, thereby preventing a host immune response.

Human alpha-folate receptor chimeric antigen receptor

The present invention relates to magnetic nanoparticles based on iron oxide having cubic shape, suitably functionalized for the release of targeting chemotherapeutic agents, i.e. selectively in the tumors being treated The invention also relates to the pharmaceutical compositions having such nanoparticles and to their use in combined oncological therapies of hyperthermia and chemotherapy, useful in particular in the treatment of ovarian tumors.

Magnetic nanoparticles for use in the treatment of tumors

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having &#x3b1;-folate receptor (FR&#x3b1;) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

Compositions and methods for treating cancer

The present invention concerns the field of cancer immunotherapy, and in particular drugs with low toxicity which can overcome drug-resistance. The present invention concerns novel bispecific antibodies which have the capability of binding both the TRAIL tumor associated antigen and the T lymphocyte CD3. The invention further relates to compositions comprising the bispecific antibodies and a labelling agent, and to pharmaceutical compositions. The present invention also relates to the use of the bispecific antibodies in the treatment of a tumor.

Bispecific antibody binding TRAIL-R2 and CD3

An isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen (PSMA) preferably in its native form on the surface of tumour cells. A conjugate of the antibody with an active ingredient and modified forms of the antigen-binding antibody fragment are also provided. The complete antibody and the antigen-recognising fragment thereof are used alone or conjugated for the treatment and the diagnosis of tumours or tissues associated to the tumour overexpressing the PSMA antigen, preferably prostatic neoplastic diseases.

Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof

Antibody or fragment thereof, which specifically binds to folate receptor-alpha (FR&#x3b1;), wherein said antibody or fragment thereof comprises a light chain whose variable region comprises at least one of the following amino acid sequences: &#x2014;RASESVSFLGINLIH (SEQ ID NO: 3), &#x2014;QASNKDT (SEQ ID NO: 4), &#x2014;LQSKNFPPYT (SEQ ID NO: 5), and wherein the constant region of said light chain is a kappa constant region.

Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma

Growing community of inventors

Milan, Italy

Mariangela Figini